FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm565321.htm

Source: Food and Drug Administration - June 29, 2017 Category: American Health Source Type: news